Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 11 May 2022

The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Wednesday, 11 May 2022. The Annual General Meeting was conducted by way of postal voting in accordance with Swedish temporary legislation. The main resolutions passed at the Meeting include the following.

 

Income statement and balance sheet as well as consolidated income statement and balance sheet

It was resolved to adopt the income statement and balance sheet, as well as the consolidated income statement and balance sheet, included in the Company’s annual report.

 

It was resolved, pursuant to the proposal from the Board of Directors, that the total profits of SEK 385,417,866.00 available to the Annual General Meeting should be carried forward.

 

The Board of Directors and Auditor

It was resolved to discharge the members of the Board of Directors and the Chief Executive Officer from liability in relation to their management of the Company’s operations during the period covered by the audit report.

 

It was resolved that the number of members of the Board of Directors appointed by the Annual General Meeting shall be five. It was resolved that the number of auditors should continue to be one.

 

For the period until the end of the next Annual General Meeting, Mia Arnhult, Lars Höckenström, Fredrik Dahl and Pia Gideon were re-elected as members of the Board of Directors, and Fredrik Mattsson was newly elected as member of the Board of Directors. Ulf Klangby has declined re-election.

 

For the period until the end of the next Annual General Meeting, Mia Arnhult was re-elected as Chairman of the Board of Directors. It was resolved to, for the period until the end of the next Annual General Meeting, re-elect the auditing firm Grant Thornton Sweden AB as auditor. It was noted that the authorized public accountant Mikael Östblom would be auditor-in-charge.

 

Fees to the Board of Directors and the Auditor

It was resolved to approve the fees to the Board of Directors as proposed by the Nomination Committee, entailing a fee of SEK 300,000.00 to the Chairman and a fee of SEK 140,000.00 to each of the other members of the Board of Directors, amounting to a total fee of SEK 860,000.00. The Annual General Meeting further resolved that a member of the Board of Directors who is also the Chairman of the Audit Committee shall be entitled to an additional fee of SEK 50,000.00, and a member of the Board of Directors who is also a member of the Audit Committee shall be entitled to an additional fee of SEK 10,000.00.

 

The Annual General Meeting approved the Nomination Committee’s proposal that the auditor’s fee shall be paid according to an approved invoice.

 

Instruction for the Nomination Committee

It was resolved, in accordance with the Nomination Committee’s proposal, to adopt the proposed instruction for the Nomination Committee, which shall be applied until a General Meeting decides otherwise.

 

Remuneration guidelines for senior management

It was resolved to approve the Board of Directors’ proposed remuneration guidelines for senior management.

 

Authorization for the Board of Directors to resolve upon share issues relating to corporate acquisitions

It was resolved, in accordance with the Board of Director’s proposal, to authorize the Board to resolve upon issues of shares and other financial instruments – with deviation from the shareholders’ preferential rights – to facilitate corporate acquisitions.

 

Establishment of employee stock option program and issue of warrants

It was resolved, in accordance with the Board of Directors’ proposal, to establish an employee stock option program for current and future employees and other key people in the Company and its subsidiaries. It was further resolved, in accordance with the Board of Directors’ proposal, upon a directed issue of not more than 328,550 warrants, in order to facilitate the Company’s delivery of shares under the employee stock option program.

 

This information was submitted for publication, through the agency of the contact persons below, on May 11, 2022, at 17:00 CET.

 

For more information, please contact:

Fredrik Alpsten, CEO
E-mail: [email protected]

Tel: +46 706 673 106

 

Sabina Berlin CFO
E-post: [email protected]
Tel: +46 739 519 502

 

About Devyser Diagnostics AB (publ)

Devyser is specialized in the development, manufacture, and sales of diagnostic kits. The products are sold to routine diagnostic laboratories in more than 45 countries. The products are used for complex DNA testing in the hereditary disease, oncology and post-transplantation monitoring fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser’s product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Devyser was founded in 2004 and is based in Stockholm, Sweden.

 

Devyser’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company’s Certified Adviser is Redeye AB, e-mail address [email protected] and telephone number +46 8 121 576 90. For more information, visit www.devyser.com.